Barinthus Biotherapeutics plc

NasdaqGM:BRNS Stock Report

Market Cap: US$44.7m

Barinthus Biotherapeutics Management

Management criteria checks 2/4

Barinthus Biotherapeutics' CEO is Bill Enright, appointed in Aug 2019, has a tenure of 5.33 years. total yearly compensation is $1.81M, comprised of 33.7% salary and 66.3% bonuses, including company stock and options. directly owns 3.09% of the company’s shares, worth $1.38M. The average tenure of the management team and the board of directors is 0.5 years and 4.9 years respectively.

Key information

Bill Enright

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage33.7%
CEO tenure5.3yrs
CEO ownership3.1%
Management average tenureless than a year
Board average tenure4.9yrs

Recent management updates

Recent updates

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Nov 19
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Aug 31
Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Jul 07
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Nov 17
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Vaccitech promotes Gemma Brown to CFO

Sep 20

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

CEO Compensation Analysis

How has Bill Enright's remuneration changed compared to Barinthus Biotherapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$2mUS$610k

-US$73m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$2mUS$569k

US$5m

Sep 30 2022n/an/a

US$11m

Jun 30 2022n/an/a

-US$1m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$3mUS$474k

-US$51m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$41m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$3mUS$350k

-US$18m

Dec 31 2019US$381kUS$128k

-US$21m

Compensation vs Market: Bill's total compensation ($USD1.81M) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.

CEO

Bill Enright (62 yo)

5.3yrs

Tenure

US$1,811,611

Compensation

Mr. William J. Enright, also known as Bill, MBA, is an Independent Director of Bullfrog AI Holdings, Inc. from February 14, 2023. He serves as Chief Executive Officer & Director of Barinthus Biotherapeutic...

Leadership Team

NamePositionTenureCompensationOwnership
William Enright
CEO & Director5.3yrsUS$1.81m3.09%
$ 1.4m
Graham Griffiths
Chief Operating Officerless than a yearUS$731.06k0.26%
$ 115.7k
Sarah Gilbert
Co-Founderno dataUS$48.98kno data
Adrian Hill
Co-Founder & Scientific Advisorno dataUS$61.61kno data
Gemma Brown
CFO & Company Secretary2.3yrsno datano data
Geoffrey Lynn
Chief Scientific Officerno datano datano data
Elizabeth Eagling-Vose
Head of Clinical Operationsno datano datano data
Bernie McDonald
Head of IPno datano datano data
Leon Hooftman
Chief Medical Officerless than a yearno datano data

0.5yrs

Average Tenure

45yo

Average Age

Experienced Management: BRNS's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
William Enright
CEO & Director5.3yrsUS$1.81m3.09%
$ 1.4m
Karen Dawes
Independent Non-Executive Director3.8yrsUS$81.69k0.0042%
$ 1.9k
Anne Phillips
Independent Non-Executive Director3.8yrsUS$81.06k0.0075%
$ 3.3k
Robin Wright
Independent Chairman of the Board6.3yrsUS$117.13k0.12%
$ 53.6k
Pierre Armand Morgon
Independent Non-Executive Director6.9yrsUS$85.42k0.026%
$ 11.7k
Alex Hammacher
Non-Executive Director4.9yrsUS$71.11k0.0075%
$ 3.3k
Benoit den Eynde
Member of Scientific Advisory Boardno datano datano data
Mark Tuthill
Member of Scientific Advisory Boardno datano datano data
Joseph C. Scheeren
Independent Non-Executive Director3.8yrsUS$79.82k0.057%
$ 25.5k

4.9yrs

Average Tenure

62yo

Average Age

Experienced Board: BRNS's board of directors are considered experienced (4.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 02:45
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Barinthus Biotherapeutics plc is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Yi ChenH.C. Wainwright & Co.
Matthew HarrisonMorgan Stanley